STING1 and bone neoplasm: To address this limitation, we have utilized a recently described nanotechnology platform (i.e., STING-NPs) to systemically deliver 2′3′-cGAMP, the endogenous ligand for STING, allowing effects of STING activation on the BM and bone tumor growth to be examined (36, 37).